Odyssey Therapeutics Secures $213M Series D to Accelerate Autoimmune Clinical Portfolio
Odyssey Therapeutics raised $213 million in an oversubscribed Series D funding round, bringing its total capital raised to almost $700 million in under four years123.
The financing will support advancement of Odyssey’s clinical and preclinical portfolio focused on treatments for autoimmune and inflammatory diseases234.
Funds are allocated to both early discovery programs and multiple clinical proof-of-concept studies, notably including a RIPK2 inhibitor utilizing PROTAC technology targeting ulcerative colitis13.
Major new investors in the round included Affinity Asset Advisors, Dimension Capital, Jeito Capital, Lightspeed Ventures, TPG Life Sciences Innovations, and Wedbush Healthcare Partners, joined by all existing investors234.
The cash infusion extends Odyssey’s cash runway to mid-2028 and ensures continued balanced capital discipline between R&D and clinical development1.
Several new representatives from leading investment firms join the Odyssey board as part of this financing, enhancing strategic governance2.
CEO Gary D. Glick emphasized the company’s commitment to transforming standards of care in autoimmune and inflammatory diseases and maintaining robust early-stage discovery operations3.
Sources:
1. https://www.ainvest.com/news/odyssey-therapeutics-213m-series-financing-strategic-inflection-point-precision-immunomodulation-autoimmune-disease-2509/
2. https://www.pharmiweb.com/press-release/2025-09-10/odyssey-therapeutics-announces-oversubscribed-213-million-series-d-financing-to-advance-clinical-pi
3. https://www.fiercebiotech.com/biotech/odyssey-therapeutics-heralds-213m-series-d-strengthen-clinical-portfolio
4. https://www.businesswire.com/news/home/20250910622822/en/Odyssey-Therapeutics-Announces-Oversubscribed-$213-Million-Series-D-Financing-to-Advance-Clinical-Pipeline-for-Autoimmune-Diseases